- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01813682
Effect of Iron-fortified TPN on Preterm Infants Anemia
The purpose of this study is to determine whether iron-fortified TPN is effective in the preventative and treatment of preterm infants. Preterm infants are at risk for anemia especially in preterm infants. Generally the smaller Birth weight and gestational age the higher anemia rate in infants. About 25% to 85% of preterm infants develop evidence of anemia during infancy,77% VLBW(very low birth weight) infants developed anemia during the hospital stay. The effects of iron deficiency are pervasive and involve multiple organ systems. Poor physical growth, gastrointestinal disturbances, thyroid dysfunction, altered immunity and temperature instability has been attributed to iron deficiency in very low birth weight infants. So it is important to provide iron for preterm infants.
As enteral nutrition is not feasible soon after birth in most preterm infants, Parenteral iron administration is an efficacious method for us to select. For most preterm infants the use of TPN(total parenteral nutrition) is very common during the first ten days of life, so we hypothesis that iron-fortified TPN may have a preventative and treatment effect on preterm infants using TPN as a supplementation of oral nutrition; Iron-fortified TPN(total parenteral nutrition) can also improve iron store status of preterm infants. The higher concentration of iron used in this study the larger preventative or treatment effect on preterm infants anemia; It is safe to add Small dose of iron agent to TPN.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Preterm infants are at high risk of anemia especially low birth weight infants, so it is important to supply iron with infants of this group.
90 preterm infants BW(birth weight) less than 2kg,entered neonatal intensive care unit(NICU) less than 72 hours and meet the Inclusion Criteria of this study will be Randomly divided into three groups, control group、 treatment group1 (200μg/kg/d,and the highest concentration of iron is ≤0.8g/100ml TPN)、treatment group2 (400μg/kg/d,and the highest concentration of iron is ≤0.8g/100ml TPN). iron supplementation period for more than ten days. For three groups, complete blood counts, differential counts, and reticulocyte counts were measured weekly in samples obtained, serum iron, iron protein, total iron binding force were measured at baseline and after 2 weeks. Through comparative analysis of three groups, to find iron-fortified TPN whether affect anemia rate and iron storage in preterm. we also selected malondialdehyde (MDA)and 8-iso-prostaglandin F2α(8-iso-PGF2α) as our concerns about iron used in TPN induces oxidative stress index.
Iron protein determination use radioimmunoassay method, serum iron and total iron binding force determination use chemical method, MDA and 8-iso-PGF2α determination use enzyme-linked immunosorbent assay method.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: qingya tang, M.D.
- Phone Number: +8613761184818
- Email: tangqingya@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Recruiting
- Xinhua Hospital
-
Contact:
- yexuan tao, PH.D.
- Phone Number: +8613818334664
- Email: taoyexuan@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Preterm infants with birth weight less than 2kg Have parenteral nutrition indication With written informed consent of parents or guardian
Exclusion Criteria:
- have already used TPN before randomization Kidney and liver function abnormal have hemolytic disease have hemorrhagic disease have Serious congenital malformation have septicemia have plethora newborn use TPN less than ten days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control group
preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
|
|
Experimental: treatment group1
preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
|
fe-1 group with TPN of iron supplementation of 200μg/kg/d.
|
Experimental: treatment group2
preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
|
fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
anemia rate
Time Frame: up to 2 weaks
|
compare the anemia rate of three groups and identify the effect of iron-fortified TPN for preterm infants.
|
up to 2 weaks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
iron status
Time Frame: baseline and more than ten days
|
Serum iron, iron protein and total iron binding force are parameters used to test the effectiveness of iron-fortified TPN used for preterm infants.
|
baseline and more than ten days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxidative stress parameters Oxidative stress parameters Oxidative stress parameters
Time Frame: baseline and more than ten days
|
we use MDA、 8-iso-prostaglandin F2α as the oxidative stress parameters to identify the safety of iron-fortified TPN used in preterm infants.
|
baseline and more than ten days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: qingya tang, M.D., Shanghai jiaotong university affiliated xinhua hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- eoitopia
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Infants
-
Hadassah Medical OrganizationWithdrawnPreterm Infants With White Matter Damage | Preterm Infants Developing Normally
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Asir John SamuelMaharishi Markendeswar University (Deemed to be University)Completed
-
Children's Hospital of Fudan UniversityCompletedPreterm InfantsChina
-
University of California, DavisCompleted
-
University of ZurichUnknownExecutive Function in Preterm Born Children: An Integrative Approach From Genetics to Brain FunctionPreterm InfantsSwitzerland
-
National Taiwan University HospitalUniversity of GeorgiaUnknown
-
Tel-Aviv Sourasky Medical CenterCompletedPreterm InfantsIsrael
-
Tel-Aviv Sourasky Medical CenterCompleted
-
Seoul National University HospitalRecruitingPreterm InfantsKorea, Republic of
Clinical Trials on treatment group1
-
Istanbul University - Cerrahpasa (IUC)CompletedDevelopment, Infant | Development DelayTurkey
-
Duygu Sultan OgeNot yet recruitingPelvic Floor Muscle Weakness
-
Hawthorne Effect Inc.Uqora, Inc.Terminated
-
Hospices Civils de LyonUnknown
-
Assistance Publique - Hôpitaux de ParisGlaxoSmithKline; Ensemble contre le SIDACompleted
-
St. Boniface HospitalAgriculture and Agri-Food CanadaActive, not recruiting
-
Gangnam Severance HospitalCompletedStomach NeoplasmKorea, Republic of
-
Universita di VeronaCompletedCerebrovascular Disorders | HemiparesisItaly
-
Chongqing University Cancer HospitalRecruiting